The results showed that SCLC patients with high VEGFR2 expression had worse prognosis, and the median PFS and OS were significantly lower than those with low VEGFR2 expression, with a statistically significant difference (P < 0.001). This evidence concerns the gene KDR and small cell lung carcinoma.